Koch Institute Members use vertebrate model organisms as a key tool to study the role of known or putative cancer genes in development and tumorigenicity; investigate the mechanisms of tumor initiation, progression and metastasis; evaluate the role of stroma and immune responses in tumorigenesis; and assess the efficacy of drugs, nanomaterials and devices in therapeutic and diagnostic applications. Thus, it is essential that Center Members are able to correctly diagnose developmental and tumor phenotypes, evaluate the underlying molecular events, and accurately and quantitatively assess drug or vaccine delivery and therapeutic response. The Koch Institute Histology Core is a Shared Resource that provides state-of-the-art histological services to support these studies. This includes assistance and/or training in tissue sectioning, slide preparation and analysis, and access to the consultative services of an internationally recognized Veterinary Pathologist, Dr. Roderick Bronson for diagnosis of tumor and developmental phenotypes. In the current period, the capabilities of this Core have been expanded and enhanced. This includes moving into a larger, custom-designed space in the new Koch Institute building, an increase in the staff and the acquisition of new instrumentation including the addition of automated immunohistochemistry and special staining capabilities. Notably, in the same period, usage of the Histology Core by Center Members increased from 53% to 67%, and included investigators from all four Programs. Thus, this Shared Resource is essential to the success of the Koch Institute mission. In the upcoming period, the Histology Core will continue to offer a wide range of state-of-the-art histological services to support the research programs of Center Members. In spite of the significant expansion of services, and the resulting increased costs of running this Core, the requested CCSG budget for Year 44 is essentially the same as the requested and recommended budget in Year 39.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014051-44
Application #
9149795
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2015-07-09
Project End
2020-04-30
Budget Start
2015-07-09
Budget End
2016-04-30
Support Year
44
Fiscal Year
2015
Total Cost
$251,024
Indirect Cost
$82,319
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Parisi, Tiziana; Balsamo, Michele; Gertler, Frank et al. (2018) The Rb tumor suppressor regulates epithelial cell migration and polarity. Mol Carcinog 57:1640-1650
Gam, Jeremy J; Babb, Jonathan; Weiss, Ron (2018) A mixed antagonistic/synergistic miRNA repression model enables accurate predictions of multi-input miRNA sensor activity. Nat Commun 9:2430
Chen, Huihui; Cho, Kin-Sang; Vu, T H Khanh et al. (2018) Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma. Nat Commun 9:3209
Tam, Brooke E; Hao, Yining; Sikes, Hadley D (2018) An examination of critical parameters in hybridization-based epigenotyping using magnetic microparticles. Biotechnol Prog 34:1589-1595
Ramadi, Khalil B; Dagdeviren, Canan; Spencer, Kevin C et al. (2018) Focal, remote-controlled, chronic chemical modulation of brain microstructures. Proc Natl Acad Sci U S A 115:7254-7259
Knouse, Kristin A; Lopez, Kristina E; Bachofner, Marc et al. (2018) Chromosome Segregation Fidelity in Epithelia Requires Tissue Architecture. Cell 175:200-211.e13
Sabari, Benjamin R; Dall'Agnese, Alessandra; Boija, Ann et al. (2018) Coactivator condensation at super-enhancers links phase separation and gene control. Science 361:
Fiedler, Eleanor R C; Bhutkar, Arjun; Lawler, Emily et al. (2018) In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1 + BCP-ALL. Blood Adv 2:1229-1242
Clancy-Thompson, Eleanor; Devlin, Christine A; Tyler, Paul M et al. (2018) Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell-Effector Responses. Cancer Immunol Res 6:1524-1536

Showing the most recent 10 out of 904 publications